An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's Disease

Summary

The purpose of this study is to assess the safety and effectiveness of BMS-986165 compared to placebo in participants with moderately to severely active Crohn's Disease.

Timeline

Start

2018-07-16

Primary completion

2022-12-12

Completion

2023-10-23

Outcome

Mixed primary results

Stopped: “Trial terminated because of lack of efficacy in the short term acute phase”

registry Placebo vs 3 mg BMS-986165; p = 0.5812; Risk Difference (RD) 4.3 (95% CI -11.0 to 19.5) NCT03599622 ↗

registry Placebo vs 3 mg BMS-986165; p = 0.0198; Risk Difference (RD) 15.0 (95% CI 3.7 to 26.3) NCT03599622 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CRAVACITINIB	Small molecule	—	—

Indications